Abstract
Representative driver oncogenes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), KRAS, and B-rapidly accelerated fibrosarcoma (BRAF) have recently been identified as new genetic aberrations in patients with non-small cell lung cancer (NSCLC). Additionally, rearranged during transfection (RET) and c-ros oncogene 1 (ROS1) fusion genes, which are minor-driver oncogenes, are each found in 1–2 % of NSCLC and represent distinct molecular subsets. Studies based on preclinical and clinical studies of several fusion-positive patients indicate that inhibiting the kinase activity of the RET and ROS1 fusion proteins is a promising therapeutic strategy. Therefore, there are several ongoing clinical trials aimed at examining the efficacy of tyrosine kinase inhibitors (TKIs) against fusion proteins in patients with fusion-positive NSCLC. Other minor gene mutations (HER2/ERBB2, NTRK1, NRG1, FGFR1/FGFR3, DDR2, and PIK3CA) that are targetable by existing TKIs have also been identified in patients with NSCLCs. It is necessary to establish systematic genomic testing algorithms to identify defined subsets of patients with NSCLC for whom effective drug therapies are available either commercially or through clinical trials.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394
Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
Kohno T, Ichikawa H, Totoki Y et al (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18:375–377
Takeuchi K, Soda M, Togashi Y et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378–381
Drilon A, Wang L, Hasanovic A et al (2013) Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3:630–635
Wu YM, Su F, Kalyana-Sundaram S et al (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3:636–647
Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519–525
Koivunen JP, Mermel C, Zejnullahu K et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275–4283
Bergethon K, Shaw AT, Ou SH et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870
Pao W, Hutchinson KE (2012) Chipping away at the lung cancer genome. Nat Med 18:349–351
Li T, Kung HJ, Mack PC, Gandara DR (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039–1049
Kohno T, Tsuta K, Tsuchihara K et al (2013) RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci 104:1396–1400
Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006
Lopez-Chavez A, Thomas A, Rajan A et al (2015) Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 33:1000–1007
Eng C (1999) RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380–393
Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365
Plaza-Menacho I, Mologni L, McDonald NQ (2014) Mechanisms of RET signaling in cancer: current and future implications for targeted therapy. Cell Signal 26:1743–1752
Lipson D, Capelletti M, Yelensky R et al (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382–384
Tsuta K, Kohno T, Yoshida A et al (2014) RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer 110:1571–1578
Matsubara D, Kanai Y, Ishikawa S et al (2012) Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol 7:1872–1876
Chao BH, Briesewitz R, Villalona-Calero MA (2012) RET fusion genes in non-small-cell lung cancer. J Clin Oncol 30:4439–4441
Gautschi O, Zander T, Keller FA et al (2013) A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 8:e43–e44
Falchook GS, Ordonez NG, Bastida CC et al (2016) Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer. J Clin Oncol 34:e141–e144
Wu H, Shih JY, Yang JC (2015) Rapid response to sunitinib in a patient with lung adenocarcinoma harboring KIF5B-RET fusion gene. J Thorac Oncol 10:e95–e96
Yoh K, Seto T, Satouchi M et al (2016) Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med
Drilon A, Rekhtman N, Arcila M et al (2016) Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an openlabel, single-centre, phase 2, single-arm trial. Lancet Oncol
Robinson DR, Wu YM, Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19:5548–5557
Chin LP, Soo RA, Soong R, Ou SH (2012) Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 7:1625–1630
Davies KD, Le AT, Theodoro MF et al (2012) Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570–4579
Ou SH, Bartlett CH, Mino-Kenudson M et al (2012) Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17:1351–1375
Sholl LM, Sun H, Butaney M et al (2013) ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 37:1441–1449
Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971
Mazieres J, Zalcman G, Crino L et al (2015) Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33:992–999
Awad MM, Katayama R, McTigue M et al (2013) Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368:2395–2401
Davies KD, Mahale S, Astling DP et al (2013) Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One 8:e82236
Davare MA, Saborowski A, Eide CA et al (2013) Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci U S A 110:19519–19524
Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310
Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694–1703
Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
Paik PK, Arcila ME, Fara M et al (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046–2051
Cardarella S, Ogino A, Nishino M et al (2013) Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 19:4532–4540
Marchetti A, Felicioni L, Malatesta S et al (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:3574–3579
McCourt CM, McArt DG, Mills K et al (2013) Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One 8:e69604
Ilie M, Long E, Hofman V et al (2013) Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 24:742–748
Pratilas CA, Hanrahan AJ, Halilovic E et al (2008) Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68:9375–9383
Hyman DM, Puzanov I, Subbiah V et al (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726–736
Gautschi O, Peters S, Zoete V et al (2013) Lung adenocarcinoma with BRAF G469 L mutation refractory to vemurafenib. Lung Cancer 82:365–367
Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365
Falchook GS, Long GV, Kurzrock R et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893–1901
Sullivan RJ, Flaherty KT (2013) Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 49:1297–1304
Lito P, Pratilas CA, Joseph EW et al (2012) Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22:668–682
Rudin CM, Hong K, Streit M (2013) Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol 8:e41–e42
Mazieres J, Peters S, Lepage B et al (2013) Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31:1997–2003
Heinmoller P, Gross C, Beyser K et al (2003) HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 9:5238–5243
Stephens P, Hunter C, Bignell G et al (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431:525–526
Perera SA, Li D, Shimamura T et al (2009) HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 106:474–479
Shimamura T, Ji H, Minami Y et al (2006) Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66:6487–6491
De Greve J, Teugels E, Geers C et al (2012) Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76:123–127
Janne PA, Ou SH, Kim DW et al (2014) Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol 15:1433–1441
Gandhi L, Bahleda R, Tolaney SM et al (2014) Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 32:68–75
Vaishnavi A, Capelletti M, Le AT et al (2013) Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19:1469–1472
Farago AF, Le LP, Zheng Z et al (2015) Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol 10:1670–1674
Fernandez-Cuesta L, Plenker D, Osada H et al (2014) CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 4:415–422
Nakaoku T, Tsuta K, Ichikawa H et al (2014) Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res 20:3087–3093
Dutt A, Ramos AH, Hammerman PS et al (2011) Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6:e20351
Weiss J, Sos ML, Seidel D et al (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93
Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543–550
Capelletti M, Dodge ME, Ercan D et al (2014) Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 20:6551–6558
Majewski IJ, Mittempergher L, Davidson NM et al (2013) Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 230:270–276
Helsten T, Elkin S, Arthur E et al (2016) The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 22:259–267
Hammerman PS, Sos ML, Ramos AH et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78–89
Bai Y, Kim JY, Watters JM et al (2014) Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res 74:7217–7228
Sun Y, Ren Y, Fang Z et al (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28:4616–4620
Kawano O, Sasaki H, Endo K et al (2006) PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54:209–215
Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26
Engelman JA, Mukohara T, Zejnullahu K et al (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116:2695–2706
Engelman JA, Chen L, Tan X et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Miyanaga, A. (2017). Minor-Driver Mutant. In: Takiguchi, Y. (eds) Molecular Targeted Therapy of Lung Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-2002-5_12
Download citation
DOI: https://doi.org/10.1007/978-981-10-2002-5_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-2000-1
Online ISBN: 978-981-10-2002-5
eBook Packages: MedicineMedicine (R0)